Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.
Anell
Anders
A
The Swedish Institute for Health Economics, 22002 Lund, Sweden. aa@ihe.se
D026683:Advisory Committees / Q000458:organization & administration*; D016527:Drug Costs; D011907:Rate Setting and Review / Q000379:methods*; D012051:Reimbursement Mechanisms / Q000191:economics* / Q000458:organization & administration